On January 19, 2019, Katrine S. Bosley, President and Chief Executive Officer of Editas Medicine, Inc., notified the company that she will step down from her position as President and Chief Executive Officer of the company. In order to ensure a smooth transition, the company entered into a letter agreement with Ms. Bosley effective as of January 19, 2019 pursuant to which Ms. Bosley agreed to a transition period as President and Chief Executive Officer ending March 1, 2019 and also entered into an Advisory Service Agreement to be effective as of March 1, 2019. Ms. Bosley also resigned as a member of the company's Board of Directors on January 19, 2019.

In connection with Ms. Bosleys separation, the Board approved the appointment of Cynthia Collins, age 60, a director of the company, as interim Chief Executive Officer effective March 1, 2019. Ms. Collins previously served as the Chief Executive Officer of Human Longevity, Inc. from January 2017 to December 2017. Prior to joining Human Longevity, Ms. Collins served as the Chief Executive Officer and GM of the Cell Therapy and Lab Business division of GE Healthcare Life Sciences, a division of General Electric Company (GE Healthcare) from April 2015 to December 2016, as the CEO, IVD, of Clarient Diagnostics, Inc., a division of GE Healthcare, from October 2013 to April 2015, as Chief Executive Officer and director of GenVec, Inc. On January 20, 2019, the Company and Ms. Collins entered into a Consulting Agreement with respect to Ms. Collins service during the transition period and as interim Chief Executive Officer.

The Consulting Agreement is effective as of February 1, 2019 and terminates upon the earlier of July 31, 2019 or the appointment of a permanent Chief Executive Officer.